Episode 4 - Trends in 2017: Power to Patients, Payers, Changes in Regulation and Lower R&D Productivity
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on November 27, 2018 01:34 ()
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 210975247 series 2376277
In this episode, I take a look at the Magic 8 Ball to determine the trends to watch out for in Pharma for 2017. Patient consumerism continues to increase while payers grow influence over which drugs to reimburse & how. Changes in regulations are expected across the board to allow novel therapies where the unspoken race to become the powerhouse for gene and cell therapy center continues around the globe. New insights are provided to whether current level of technology is viable in the area of gene and cell therapy as well as impact of biosimilars in the market. Last but not least, R&D productivity continues to wither as newer incremental jumps are not incorporated to make R&D in pharma more productive - regulation changes may help resolve some of these challenges.
11 episodes